Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med.343(13), 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Romano S, Cannoni S. Epidemiology and current treatment of multiple sclerosis in Europe today. J. Rehabil. Res.39(2), 175–185 (2002).
   PubMed Web of Science ®Google Scholar
• Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann. Neurol.29(5), 548–555 (1991).
   PubMed Web of Science ®Google Scholar
• Cutter GR. Measures of impairment and disability. In: Multiple Sclerosis Therapeutics Rudick RA, Goodkin DE (Eds), Martin Dunitz Ltd, London, UK, 19–30 (1999 ).
   Google Scholar
• Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain127(Pt 7), 1463–1478 (2004).
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol.58(6), 840–846 (2005).
   PubMed Web of Science ®Google Scholar
• Sharrack B, Hughes R, Soudain S et al. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain122(Pt 1), 141–159 (1999).
   PubMed Web of Science ®Google Scholar
• Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and disability by interferon-β1a subcutaneously in multiple sclerosis. Ann. Neurol.46(2), 197–206 (1999).
   PubMed Web of Science ®Google Scholar
• Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon β-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology60(1), 44–51 (2003).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33(11), 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Bastianello S, Koudraivtseva T et al. Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short-term study in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry61(3), 251–258 (1996).
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Group and the University of British Columbia MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis. Final outcome of the randomised controlled trial. Neurology45(7), 1277–1285 (1995).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β 1a for disease progression in relapsing-remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol.39(3), 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• European Study on Interferon β-1b in Secondary-Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet352(9139), 1491–1497 (1998).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med.343(13), 898–904 (2000).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet357(9268), 1576–1582 (2001).
   PubMed Web of Science ®Google Scholar
• The Prisms Study Group and the University of British Columbia MS/MRI Analysis Group. Prisms-4. Long-term efficacy of interferon-β-1a in relapsing MS. Neurology56(12), 628–1236 (2001).
   PubMed Web of Science ®Google Scholar
• Secondary Progressive Efficacy Clinical Trials of Recombinant Interferon β1a in MS (Spectrims) Study Group. Randomized controlled trial of interferon-β-1a in secondary progressive MS: clinical results. Neurology56(11), 1496–1504 (2001).
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P et al. Every-other-day interferon β-1b versus once-weekly interferon β-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet359(9316), 1453–1460 (2002).
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, Weinshenker B. The North American Study Group on Interferon β-1b in Secondary Progressive MS. Interferon β-1b in secondary progressive MS: results from a 3-year controlled study. Neurology63(10), 1788–1795 (2004).
   PubMed Web of Science ®Google Scholar
• Ozakbas S, Ormeci B, Egemen I. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies. J. Neurol. Sci.232(1–2), 65–69 (2005).
   PubMed Web of Science ®Google Scholar
• Ozakbas S, Ormeci B, Egemen I. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies. J. Neurol. Sci.232(1–2), 65–69 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen J, Fischer J, Bolibrush B et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology54(4), 802–806 (2000).
   PubMed Web of Science ®Google Scholar
• Cohen J, Cutter G, Fischer J et al. Use of the multiple sclerosis functional composite as an outcome measure in a Phase 3 clinical trial. Arch. Neurol.58(6), 961–967 (2001).
   PubMed Web of Science ®Google Scholar
• Cutter GR, Baier M, Rudick R et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain122(Pt 5), 871–882 (1999).
   PubMed Web of Science ®Google Scholar
• Patzold T, Schwengelbeck M, Ossege L-M et al. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol. Scand.105(3), 164–168 (2002).
   PubMed Web of Science ®Google Scholar
• Fachenecker P, Kumpfel T, Kallmann K et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult. Scler.8(6), 523–526 (2002).
   PubMedGoogle Scholar
• Hobart J, Riazi A, Thompson A et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain129, 224–234 (2005).
   PubMedGoogle Scholar
• Miller D, Ruddick R, Cutter G et al. Clinical significance of the multiple sclerosis functional composite relationship to patient-reported quality of life. Arch. Neurol.57(9), 1319–1324 (2000).
   PubMed Web of Science ®Google Scholar
• Fischer J, Larocca N, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult. Scler.5(4), 251–259 (1999).
   PubMed Web of Science ®Google Scholar
• Huijbregts SC, Kalkers NF, De Sonneville LM, De Groot V, Reuling IE, Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology63(2), 335–339 (2004).
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology41(5), 685–691 (1991).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Martinelli V et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J. Neurol. Sci.132(2), 222–227 (1995).
   PubMed Web of Science ®Google Scholar
• Filippi M, Tortorella C, Rovaris M et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry68(2), 157–161 (2000).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Carone DA, Bakshi R. Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis. J. Neuroimaging14(3 Suppl.), 36S–45S (2004).
   PubMed Web of Science ®Google Scholar
• van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn. Reson. Med.36(4), 632–636 (1996).
   PubMedGoogle Scholar
• Zivadinov R, De Masi R, Nasuelli D et al. MRI techniques and cognitive impairment in the early Phase of relapsing-remitting multiple sclerosis. Neuroradiology43(4), 272–278 (2001).
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Sepcic J, Nasuelli D et al. A longitudinal study of brain atrophy and cognitive disturbances in the early Phase of relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry70(6), 773–780 (2001).
   PubMed Web of Science ®Google Scholar
• Edwards SGM, Liu C, Blumhardt LD. Cognitive correlates of supratentorial atrophy on MRI in multiple sclerosis. Acta Neurol. Scand.104(4), 214–223 (2001).
   PubMed Web of Science ®Google Scholar
• Huber SJ, Bornstein RA, Rammohan KW, Christy JA, Chakeres DW, McGhee RB. Magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J. Neuropsychiatry Clin. Neurosci.4(2), 152–158 (1992).
   PubMed Web of Science ®Google Scholar
• Rao SM, Bernardin L, Leo GJ, Ellington L, Ryan SB, Burg LS. Cerebral disconnection in multiple sclerosis. Relationship to atrophy of the corpus callosum. Arch. Neurol.46(8), 918–920 (1989).
   PubMed Web of Science ®Google Scholar
• Amato MP, Bartolozzi ML, Zipoli V et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology63(1), 89–93 (2004).
   PubMed Web of Science ®Google Scholar
• Camp SJ, Stevenson VL, Thompson AJ et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain128(12), 2891–2898 (2005).
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology39(2 Pt 1), 161–166 (1989).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Zivadinov R, Carone DA et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. Am. J. Neroradiol.26(7), 1824–1831 (2005).
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: II. Impact on employment and social function. Neurology41(5), 692–696 (1991).
   PubMed Web of Science ®Google Scholar
• Amato MP, Ponziani G, Bracco L, Siracusa G, Amaducci L. Cognitive impairment in early-onset multiple sclerosis. Patterns, predictors, and impact on everyday life in a 4-year follow-up. Arch. Neurol.52(2), 168–172 (1995).
   PubMed Web of Science ®Google Scholar
• Knight RG, Devereux RC, Godfrey HP. Psychosocial consequences of caring for a spouse with multiple sclerosis. J. Clin. Exp. Neuropsychol.19(1), 7–19 (1997).
   PubMed Web of Science ®Google Scholar
• Benedict RH. Integrating cognitive function screening and assessment into theroutine care of multiple sclerosis patients. CNS Spectr.10(5), 384–391 (2005).
   PubMed Web of Science ®Google Scholar
• Swirsky-Sacchetti T, Field HL, Mitchell DR et al. The sensitivity of the mini-mental state exam in the white matter dementia of multiple sclerosis. J. Clin. Psychol.48(6), 779–786 (1992).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Munschauer F, Linn R et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult. Scler.9(1), 95–101 (2003).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult. Scler.10(6), 675–678 (2004).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Fischer JS, Archibald CJ et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin. Neuropsychol.16(3), 381–397 (2002).
   PubMed Web of Science ®Google Scholar
• Wilken JA, Kane R, Sullivan CL et al. The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Mult. Scler.9(2), 119–127 (2003).
   PubMed Web of Science ®Google Scholar
• Bagnato F, Frank J. The role of nonconventional magnetic resonance imaging techniques in demyelinating disorders. Curr. Neurol. Neurosci. Rep.3(3), 238–245 (2003).
   PubMed Web of Science ®Google Scholar
• Miller DH, Albert PS, Barkhof F et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann. Neurol.39(1), 6–16 (1996).
   PubMed Web of Science ®Google Scholar
• McFarland HF, Barkhof F, Antel J, Miller DH. The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult. Scler.8(1), 40–51 (2002).
   PubMed Web of Science ®Google Scholar
• Miller DH, Rudge P, Johnson G et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain111(Pt 4), 927–938 (1988).
   PubMedGoogle Scholar
• Kermode AG, Thompson AJ, Tofts P et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain113(Pt 5), 1477–1489 (1990).
   PubMed Web of Science ®Google Scholar
• Miller DH, Barkhof F, Nauta JJ. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain116, 1077–1094 (1993).
   PubMed Web of Science ®Google Scholar
• McFarland HF, Frank JA, Albert PS et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol.32(6), 758–766 (1992).
   PubMed Web of Science ®Google Scholar
• Filippi M, Yousry T, Campi A et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology46(2), 379–384 (1996).
   PubMedGoogle Scholar
• Filippi M, Campi A, Martinelli V et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry59(5), 540–544 (1995).
   PubMed Web of Science ®Google Scholar
• Cotton F, Weiner HK, Jolesz FA, Guttmann CR. MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology60(4), 640–646 (2003).
   PubMed Web of Science ®Google Scholar
• Gupta S, Solomon JM, Tasciyan TA et al. Interferon-β-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult. Scler.11(6), 658–668 (2005).
   PubMed Web of Science ®Google Scholar
• Bagnato F, Jeffries N, Richert N et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain126(Pt 8), 1782–1789 (2003).
   PubMed Web of Science ®Google Scholar
• Campi A, Filippi M, Comi G, Scotti G, Gerevini S, Dousset V. Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis. Neuroradiology38(2), 115–119 (1996).
   PubMedGoogle Scholar
• Barkhof F, McGowan JC, van Waesberghe JH, Grossman RI. Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. J. Neurol. Neurosurg. Psychiatry64(Suppl. 1), S77–S79 (1998).
   Google Scholar
• Zivadinov R, Bagnato F, Nasuelli D et al. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J. Neurol. Sci.223(20), 185–193 (2004).
   PubMed Web of Science ®Google Scholar
• Minneboo A, Uitdehaag BM, Ader HJ, Barkhof F, Polman CH, Castelijns JA. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. Neurology65(1), 56–61 (2005).
   PubMedGoogle Scholar
• Kappos L, Moeri D, Radue EW et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet353(9157), 964–969 (1999).
   PubMed Web of Science ®Google Scholar
• Rudick Ra, Lee JC, Simon J et al. Defining interferon β response status in multiple sclerosis patients. Ann. Neurol.56(4), 548–555 (2004).
   PubMed Web of Science ®Google Scholar
• Li DKB, Zhao G, Paty DW. T2 hyperintensities: finding and significance. Neuroimaging Clin. N. Am.10(4), 717–738 (2000).
   PubMedGoogle Scholar
• Barkhof F, Karas GB, van Walderveen MA. T1 hypointensities and axonal loss. Neuroimaging Clin. N. Am.10(4), 739–752 (2000).
   PubMed Web of Science ®Google Scholar
• van Walderveen MAA, Kamphorst W, Scheltens P et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology50(5), 1282–1288 (1998).
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Bakshi R. Neurological disability and central nervous system atrophy in multiple sclerosis. In: Brain and Spinal Cord Atrophy in Multiple Sclerosis. Zivadinov R, Bakshi R(Eds). Nova Biomedical Books, NY, USA, 113–136 (2004).
   Google Scholar
• Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain125(Pt 8), 1676–1695 (2002).
   PubMed Web of Science ®Google Scholar
• Tedeschi G, Ravorgna L, Russo P et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology65(2), 280–285 (2005).
   PubMedGoogle Scholar
• Pagani E, Rocca MA, Gallo A et al. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. Am. J. Neroradiol.26(2), 341–346 (2005).
   PubMed Web of Science ®Google Scholar
• Losseff NA, Wang L, Lai HM et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain119(Pt 6), 2009–2019 (1996).
   PubMed Web of Science ®Google Scholar
• Dalton CM, Brex PA, Gordon R et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the development of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry73(2), 141–147 (2002).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Fischer E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology53(8), 1698–1704 (1999).
   PubMed Web of Science ®Google Scholar
• Ge Y, Grossman RI, Udupa Y et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology214(3), 665–670 (2000).
   PubMed Web of Science ®Google Scholar
• Stevenson VL, Miller DH, Leary SM et al. One year follow up study of primary and transitional progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry68(6), 713–718 (2000).
   PubMedGoogle Scholar
• Finamore L, Ohayon JM, Calabrese A, Richert NS, McFarland H, Bagnato F. Yearly clinical and imaging follow-up of patients with multiple sclerosis: a 14year study. Mult. Scler.11(Suppl. 1) (2005) (Abstract 231).
   Google Scholar
• Richert ND, Frank JA. Magnetization transfer imaging to monitor clinical trials in multiple sclerosis. Neurology53(5 Suppl. 3), S29–S32 (1999).
   Google Scholar
• Arnold DL, De Stefano N, Narayanan S, Matthews PM. Proton MR spectroscopy in multiple sclerosis. Neuroimaging Clin. N. Am.10(4), 789–798 (2000).
   PubMedGoogle Scholar
• Rovaris M, Gass A, Bammer R et al. Diffusion MRI in multiple sclerosis. Neurology65(10), 1526–1532 (2005).
   PubMed Web of Science ®Google Scholar
• Tartaglia C, Arnold DL. The role of MRS and fMRI in multiple sclerosis. Adv. Neurol.98, 185–202 (2006).
   PubMedGoogle Scholar
• Clare S, Jezzard P. Rapid T1 mapping using multislice echo planar imaging. Magn. Reson. Med.45(4), 630–634 (2001).
   PubMed Web of Science ®Google Scholar
• Scheffler K, Hennig J. T1 Quantification with inversion recovery trueFISP. Magn. Reson. Med.45(4), 720–723 (2001).
   PubMed Web of Science ®Google Scholar
• Deoni SCL, Rutt BK, Peters TM. Rapid combined T1 and T2 mapping using gradient recalled acquisition in the steady state. Magn. Reson. Med.49, 515–526 (2003).
   PubMed Web of Science ®Google Scholar
• Barbosa S, Blumhardt LD, Roberts N, Lock T, Edwards RHT. Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the “invisible” lesion load. Magn. Res. Imaging12(1), 33–42 (1994).
   PubMedGoogle Scholar
• Armspach J-P, Gounot D, Rumbach L, Chambron J. In vivo determination of multiexponential T2 relaxation in the brain of patients with multiple sclerosis. Magn. Res. Imaging9(1), 107–113 (1991).
   PubMedGoogle Scholar
• Haughton VM, Yetkin FZ, Rao SM et al. Quantitative MR in the diagnosis of multiple sclerosis. Magn. Reson. Med.26(1), 71–78 (1992).
   PubMedGoogle Scholar
• Lacomis D, Osbakken M, Gross G. Spin-lattice relaxation (T1) Times of cerebral white matter in multiple sclerosis. Magn. Reson. Med.3(2), 194–202 (1986).
   PubMed Web of Science ®Google Scholar
• van Walderveen MAA, Kamphorst W, Scheltens P et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology50(5), 1282–1288 (1998).
   PubMed Web of Science ®Google Scholar
• Larsson HBW, Frederiksen J, Petersen J et al. Assessment of demyelination, oedema and gliosis by in vivo determination of T1 and T2 in the brain of patients with acute attack of multiple sclerosis. Magn. Reson. Med.11(3), 337–348 (1989).
   PubMedGoogle Scholar
• Parry A, Clare S, Jenkinson M, Smith S, Palace J, Matthews PM. White matter and lesion T1 relaxation times increase in parallel and correlate with disability in multiple sclerosis. J. Neurol.249(9), 1279–1286 (2002).
   PubMed Web of Science ®Google Scholar
• Griffin CM, Parker GJM, Barker GJ, Thompson AJ, Miller DH. MTR and T1 provide complementary information in MS NAWM, but not in lesions. Mult. Scler.6(5), 327–331 (2000).
   PubMed Web of Science ®Google Scholar
• Lanczos C. Applied AnalysisPrentice-Hall, NJ, USA (1956).
   Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain128(Pt 11), 2705–2712 (2005).
   PubMed Web of Science ®Google Scholar
• Sailer M, Fischl B, Salat D et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain126(Pt 8), 1734–1744 (2003).
   PubMed Web of Science ®Google Scholar
• De Stefano N, Matthews PM, Filippi M et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology60(7), 1157–1162 (2003).
   PubMed Web of Science ®Google Scholar
• Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage23(3), 1168–1175 (2004).
   PubMed Web of Science ®Google Scholar
• Calabrese M, Cao M, Gupta S et al. Neocortical damage is early and diffuse in patients with multiple sclerosis. Mult. Scler.11(Suppl. 1), 9 (2005).
   Google Scholar
• Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry25, 315–320 (1962).
   PubMed Web of Science ®Google Scholar
• Lumsden CE. The neuropathology of multiple sclerosis. In: Handbook of Clinical Neurology (Volume 9).Vinken PJ, Bruyn GW (Eds). Amsterdam, Netherlands 217–309 (1970).
   Google Scholar
• Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocytes infiltration. Mult. Scler.9(4), 323–331 (2003).
   PubMed Web of Science ®Google Scholar
• Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain122(Pt 1), 17–26 (1999).
   PubMed Web of Science ®Google Scholar
• Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neuritis, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol.50(3), 389–400 (2001).
   PubMed Web of Science ®Google Scholar
• Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol.62(7), 723–732 (2003).
   PubMed Web of Science ®Google Scholar
• Brink BP, Veerhuis R, Breij EC, van der Valk P, Dijkstra CD, Bo L. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J. Neuropathol. Exp. Neurol.64(2), 147–155 (2005).
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Am. J. Neroradiol.26(3), 572–577 (2005).
   PubMed Web of Science ®Google Scholar
• Miller DH, Thompson AJ, Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J. Neurol.250(12), 1407–1419 (2003).
   PubMed Web of Science ®Google Scholar
• Geurts JJ, Pouwels PJW, Uitdehaag BMJ, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology236(1), 254–260 (2005).
   PubMed Web of Science ®Google Scholar
• Bagnato F, Butman J, Gupta S et al.In vivo detection of cortical plaques by magnetic resonance imaging in patients with multiple sclerosis. Am. J. Neroradiol. (2006) (In press).
   PubMedGoogle Scholar
• Bernasconi N, Arnold DL. Multispectral high-resolution MRI of cortical pathology in multiple sclerosis. Mult. Scler.11(Suppl. 1), 540 (2005).
   Google Scholar
• Bagnato F, Talagala L, Calabrese A et al.In vivo visualization of cortical lesions by 3 Tesla magnetic resonance imaging in patients with multiple sclerosis. Mult. Scler.11(Suppl. 1), 670 (2005).
   Google Scholar
• Tench CR, Morgan PS, Jaspan T, Auer DP, Constantinescu CS. Spinal cord imaging in multiple sclerosis. J. Neuroimaging15, 94S–102S (2005).
   Google Scholar
• Rocca MA, Hickman SJ, Bo L et al. Imaging spinal cord damage in multiple sclerosis, J. Neuroimaging15, 297–304 (2005).
   PubMedGoogle Scholar
• Pierre-Jerome C, Arslan A, Bekkelund SI. MRI of the spine and spinal cord: imaging techniques, normal anatomy, artifacts, and pitfalls. J. Manipul. Phys. Ther.23, 470–476 (2000).
   PubMed Web of Science ®Google Scholar
• Pestalozza IF, Pozzilli C, Di Legge S et al. Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Mult. Scler.11(4), 390–394 (2005).
   PubMedGoogle Scholar
• Miller D, Barckhof F, Montalban X et al. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol.4, 281–288 (2005).
   PubMed Web of Science ®Google Scholar
• Paolillo A, Piattella MC, Pantano P et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J. Neurol.251(4), 432–439 (2004).
   PubMedGoogle Scholar
• Fernando KT, McLean MA, Chard DT et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain127, 1361–1369 (2004).
   PubMed Web of Science ®Google Scholar
• Hoult DI, Chen CN, Sank VJ. The field strength dependence of NMR imaging. II. Arguments concerning an optimal field strength. Magn. Reson. Med.3(5), 730–746 (1986).
   PubMedGoogle Scholar
• Bottomley PA, Foster TH, Argersinger RE et al. A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1–100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. Med. Phys.11(4), 425–448 (1984).
   PubMed Web of Science ®Google Scholar
• Lee DH, Vellet AD, Eliasziw M et al. MR imaging field strength: prospective evaluation of the diagnostic accuracy of mr for diagnosis of multiple sclerosis at 0.5 and 1.5 T. Radiology194(1), 257–262 (1995).
   PubMedGoogle Scholar
• Jack CR, Berquist TH, Miller GM et al. Field strength in neuro-MR imaging: a comparison of 0.5 t and 1.5 T. J. Comput. Assist. Tomogr.14(4), 505–513 (1990).
   PubMedGoogle Scholar
• Schima VW, Wimberger D, Schneider B, Stiglbauer R, Asenbaum S, Imhof H. Bedeutung der Magnetfeldstärke in der MR-Diagnostik der multiplen Sklerose: Ein Vergleich von 0,5 und 1,5T. Fortschr. Röntgenstr.58, 368–371 (1993).
   Google Scholar
• Ertl-Wagner BB, Reith W, Sartor K. Low field-low cost: can low-field magnetic resonance systems replace high-field magnetic resonance systems in the diagnostic assessment of multiple sclerosis patients? Eur. Radiol.11(8), 1490–1494 (2001).
   PubMedGoogle Scholar
• Sicotte NL, Voskuhl RR, Bouvier S, Klutch R, Cohen MS, Mazziotta JC. Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla. Invest. Radiol.38(7), 423–427 (2003).
   PubMed Web of Science ®Google Scholar
• Erskine MK, Cook LL, Riddle JR, Mitchell JR, Karlik SJ. Resolution-dependent estimates of multiple sclerosis lesion loads. Can. J. Neurol. Sci.32, 205–212 (2005).
   PubMedGoogle Scholar
• Keiper MD, Grossman RI, Hirsch JA et al. MR identification of white matter abnormalities in multiple sclerosis: a comparison between 1.5 T and 4 T. Am. J. Neroradiol.19(8), 1489–1493 (1998).
   PubMedGoogle Scholar
• Desai N, Runge VM. Contrast use at low field: a review. Top. Magn. Reson. Imaging14(5), 360–364 (2003).
   PubMedGoogle Scholar